Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Racura OncologyASX:RAC +2.27%23 3-Year EPS without NRI Growth Rate is 27.30% as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 23/100. Among 1,162 Biotechnology companies, Racura Oncology ranks better than 63.6% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 27.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -0.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 10 years, the highest 3-Year average EPS without NRI Growth Rate of Racura Oncology was 27.30% per year. The lowest was -20.50% per year. And the median was -16.60% per year.
Racura Oncology (ASX:RAC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Racura Oncology 3-Year EPS without NRI Growth Rate Related Terms
ASX:RAC vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Racura Oncology's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Racura Oncology's 3-Year EPS without NRI Growth Rate falls into.
Racura Oncology 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 27.30% mean?
Racura Oncology (ASX:RAC) has a 3-Year EPS without NRI Growth Rate of 27.30% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #423 out of 1162 companies in the Biotechnology industry, placing it in the top 36.4%.
Is Racura Oncology's 3-Year EPS without NRI Growth Rate too high?
Racura Oncology's current 3-Year EPS without NRI Growth Rate is 27.30%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Racura Oncology's value of 27.30% is 68.5% above this industry median. Based on the distribution chart, Racura Oncology ranks #423 out of 1162 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Racura Oncology has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #423 out of 1162 companies for 3-Year EPS without NRI Growth Rate. This puts Racura Oncology in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Racura Oncology's value of 27.30% is 68.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Racura Oncology's current 3-Year EPS without NRI Growth Rate of 27.30% is 68.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Racura Oncology and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current 3-Year EPS without NRI Growth Rate is 27.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current 3-Year EPS without NRI Growth Rate of 27.30%. The current 3-Year EPS without NRI Growth Rate is 27.30% and 68.5% above the Biotechnology industry median of 16.20. Racura Oncology's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current 3-Year EPS without NRI Growth Rate is 27.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
23GF Score
Get the complete analysis for ASX:RAC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
